Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Interest & Investment Income: 2013-2024

Historic Interest & Investment Income for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to $2.2 million.

  • Zevra Therapeutics' Interest & Investment Income rose 120.50% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 109.97%. This contributed to the annual value of $2.2 million for FY2024, which is 52.10% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Interest & Investment Income of $2.2 million as of FY2024, which was down 52.10% from $4.5 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Interest & Investment Income ranged from a high of $4.5 million in FY2023 and a low of $89,000 during FY2020.
  • For the 3-year period, Zevra Therapeutics' Interest & Investment Income averaged around $2.7 million, with its median value being $2.2 million (2024).
  • In the last 5 years, Zevra Therapeutics' Interest & Investment Income slumped by 71.20% in 2020 and then surged by 479.69% in 2022.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Interest & Investment Income stood at $89,000 in 2020, then surged by 193.26% to $261,000 in 2021, then soared by 479.69% to $1.5 million in 2022, then surged by 200.13% to $4.5 million in 2023, then tumbled by 52.10% to $2.2 million in 2024.